GeoVax Labs, Inc. (Nasdaq: GOVX), a leader in developing immunotherapies and vaccines for cancers and infectious diseases, is set to disclose its third quarter 2024 financial results on November 12, 2024, after the U.S. markets close. A subsequent conference call and webcast at 4:30 p.m. ET will offer a corporate update and financial discussion, accessible via registration and on the company's website under the 'Events and Presentations' section.
The timing of this report is pivotal as GeoVax advances its clinical programs, notably the GEO-CM04S1 COVID-19 vaccine, which is under a BARDA-funded Phase 2b clinical trial involving 10,000 participants. This trial aims to compare GEO-CM04S1's effectiveness against an approved COVID-19 vaccine, marking a significant milestone in the company's research efforts with potential global health implications.
Additionally, GeoVax is progressing with Gedeptin®, an innovative oncolytic solid tumor gene-directed therapy, following a successful Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 trial, planned for the first half of 2025, will explore Gedeptin® in combination with an immune checkpoint inhibitor for recurrent head and neck cancer, offering hope for new treatment pathways.
The forthcoming financial and corporate update is highly anticipated by investors and stakeholders, providing insights into GeoVax's financial health, clinical advancements, and strategic direction. The company's dedication to tackling pressing health challenges through its diverse pipeline reflects its role in the broader medical and public health landscape.
For those interested in the webcast, details are available on the GeoVax website, ensuring stakeholders have access to critical information for informed decision-making. The archived webcast will remain accessible for 90 days post-event, facilitating thorough analysis of GeoVax's progress and future outlook.
